For those seeking a promising investment opportunity in the cannabis market, Rodedawg International Industries, Inc. (OTC: RWGI)'s progress on its 2024 roadmap is a compelling proposition. The company's strategic approach, coupled with regular updates on its growth and milestones, points to the potential for expansion in the emerging cannabis industry.
As 4/20 approaches, it's a perfect time to check in on cannabis stocks. After years of stagnation, the sector is experiencing a resurgence, thanks to several encouraging factors that have pushed it higher in recent weeks.
For starters, the growing support for legalization among Americans—now at about 88%, according to Pew Research—could make cannabis a key topic in the upcoming U.S. elections. Candidates who support legalization may see a boost in their ratings, which could drive the market even further.
Florida is one state that may soon legalize adult-use cannabis. The Florida Supreme Court has proposed Amendment 3, which, if approved, could take effect in May 2025. There's also speculation about potential cannabis rescheduling by the DEA before the November election, which could further impact the sector.
With all these factors at play, cannabis stocks could see even higher highs. Let's take a look at four potential players in the sector!
Curaleaf Holdings, Inc. (OTCQX: CURLF) is a leading international cannabis provider, offering quality and reliability in the industry. Known for its brands Curaleaf, Select, and Grassroots, the company serves both medical and adult-use markets. In the U.S., it operates in 17 states with 145 dispensaries and employs over 5,600 people worldwide. Curaleaf International is the largest vertically integrated cannabis company in Europe, combining pioneering research with advanced cultivation and production.
In the fourth quarter of 2023, Curaleaf reported record revenue of $345.3 million, a 4% increase from the previous quarter. Adjusted gross margin was 46%, with adjusted EBITDA of $83 million, representing 24% of sales. Full-year revenue reached $1.35 billion, up 6% from 2022. Despite facing a net loss of $281.2 million for the year, Curaleaf's gross profit and EBITDA margins show strong potential for growth.
Operational highlights include significant expansions in states like Florida and New York and an uplisting to the Toronto Stock Exchange in December 2023. Curaleaf also launched new products such as Briq vapes and Zero Proof drinkables.
In major news, Curaleaf announced the acquisition of Northern Green Canada, a Canadian cannabis producer with EU-GMP certification. This deal solidifies Curaleaf's position in the European market and expands its presence in North America, Europe, and Australasia. The acquisition will provide high-quality, indoor-grown cannabis to meet growing demand, particularly in Germany.
Curaleaf's recent achievements and strategic expansions demonstrate its commitment to enhancing its global presence and solidifying its role as a key player in the cannabis industry. The company will report its Q1 2024 results on May 9, 2024.
Cresco Labs, Inc. (OTCQX: CRLBF) is a leading cannabis company with a strong focus on building national brands and providing a consumer-centered retail experience. The company operates under the Sunnyside dispensary brand and is known for its commitment to quality, safety, and community engagement.
Cresco Labs has a portfolio of brands such as Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindys, and Remedi. These brands offer a variety of products, including flowers, vapes, concentrates, topicals, edibles, and tinctures.
The company recently announced the promotion of Greg Butler to president, recognizing his contributions to Cresco Labs and his ability to lead the company into the future. Butler will oversee all aspects of the company's operations, including production, retail, marketing, sales, corporate planning, and investor relations.
Cresco Labs' strategic focus on core markets has led to continued growth, as evidenced by the opening of new Sunnyside dispensaries, including a recent one in Gettysburg, Pennsylvania. The company holds the number one market share position in Illinois, Pennsylvania, and Massachusetts.
Cresco Labs' financial performance demonstrates its progress and efficiency in the cannabis industry. In the fourth quarter of 2023, the company reported revenue of $188 million, adjusted gross profit of $100 million, and adjusted EBITDA of $55 million. For the full year of 2023, Cresco Labs reported revenue of $771 million and adjusted EBITDA of $174 million.
The company's focus on cost management, margin expansion, and profitability has resulted in significant improvements in its financials. Cresco Labs continues to prioritize its core strategy while positioning itself for future growth opportunities in the cannabis industry.
Investors looking for growing companies in the cannabis segment may find Cresco Labs to be an attractive option, given its strong market position, robust portfolio, and dedication to responsible industry practices.
BYND Cannasoft Enterprises Inc. (NNASDAQ: BCAN) is an Israeli-based integrated software and cannabis company focused on the women's health and wellness market. Leveraging its experience in customer relationship management (CRM) software, BYND Cannasoft is developing innovative platforms for the medical cannabis industry and wellness technologies tailored for women's health.
The company reported a challenging financial year ending December 31, 2023, with revenue down 4% year-over-year to $1,076,861 and a drastic increase in net loss to $18,495,121, primarily due to impairments. BYND Cannasoft faces significant hurdles as it navigates changes in its core activities in Israel, in addition to the difficult war in Gaza, which affected operations.
To address these challenges, BYND Cannasoft announced the pricing of a $7 million underwritten public offering in March 2024 and a 1-for-190 reverse stock split. These actions aimed to consolidate the share structure and raise funds for further development.
The company's focus on the Fem-Tech market presents an opportunity in a sector expected to grow to $139.51 billion by 2031. BYND Cannasoft is using its Smart Delivery System (SDS) to create innovative products for women's sports, hair, and cosmetics sectors. These include smart cosmetic face devices, hair growth brushes, and muscle pain relief regulators.
The company also plans to capitalize on the growing CBD market, expected to reach $36 billion within a decade. In partnership with Foria, BYND Cannasoft aims to offer CBD-based products for personal care and wellness.
While the company has potential in emerging markets, it faces challenges such as stiff competition and regulatory hurdles. Its success will hinge on its ability to navigate these obstacles and achieve sustained profitability. Investors should closely watch BYND Cannasoft's progress in product development and market penetration for long-term potential.
Rodedawg International Industries, Inc. (OTC: RWGI) is a company focused on the regulated California cannabis market, engaging in various sectors such as cultivation, distribution, manufacturing, and retail dispensaries. Through its wholly owned subsidiary, Parabola Mgmt. LLC, Rodedawg has expanded its operations and strategically acquired licenses to solidify its market presence.
In January 2024, RWGI made significant strides toward growth by acquiring a new California cannabis distributor license in Coachella, California. This achievement aligns with the company's roadmap and first-quarter milestones, showcasing RWGI's commitment to rapidly growing its cannabis license portfolio. This strategic move aims to increase the company's revenue streams and pave the way toward its ambitious goal of $7 million in annual revenue.
RWGI has also accelerated sales of hemp and cannabis-derived isolates. In the previous quarter, the company invested over six figures in a manufacturing facility for the extraction of cannabis-derived isolates from hemp. This significant investment has enabled RWGI to reach 65% production capacity, contributing to rapid revenue growth and establishing the company as a leader in the global cannabis market.
The company's latest updates from April 16, 2024, highlight RWGI's diverse enterprise, which includes the following areas of focus:
Costa Mesa License: The company operates under a Costa Mesa license for manufacturing, distribution, and off-site delivery.
Coachella Facility: RWGI procures hemp-derived isolates both for itself and as a service for other producers.
Proprietary Brands: RWGI owns proprietary cannabis retail brands, such as Brother Buds and Tree Moguls.
Elixicure: RWGI produces a proprietary and trademarked topical pain relief roll-on and spray.
Furthermore, RWGI has initiated the cancellation of over 100 million outstanding shares, which could enhance shareholder value and reflect the company's focus on revenue growth. This decision complements the consistent progress the company has shown in its operations and revenue generation.
RWGI's financial statements reveal a remarkable increase in revenues, which rose from $30,000 in December 2022 to $103,868 in December 2023. This substantial growth indicates operational efficacy and a strong upward trajectory, which is crucial for potential investors.
For those seeking a promising investment opportunity in the cannabis market, Rodedawg International Industries, Inc.'s (OTC: RWGI) progress on its 2024 roadmap is a compelling proposition. The company's strategic approach, coupled with regular updates on its growth and milestones, points to the potential for expansion in the emerging cannabis industry.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) has been retained by Awareness Consulting to assist in the production and distribution of content related to JEWL. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content.
Contact Details
CapitalGainsReport
Mark McKelvie
+1 585-301-7700
